Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fermented cha-miang extract (FCME) is a processed botanical extract derived from the leaves of *Camellia sinensis* var. *assamica*, a tea variety native to Southeast Asia. The fermentation process, which produces a traditional product known as 'Miang' in Northern Thailand, enhances the extract's antioxidant profile, particularly its ability to scavenge ABTS radicals. FCME is characterized by a high concentration of polyphenols and catechins. Pharmacological studies in animal models indicate that FCME exerts potent anti-obesity and anti-diabetic effects, including the reduction of body weight, plasma insulin levels, and insulin resistance. It also improves lipid profiles by lowering total cholesterol, triglycerides, and LDL-cholesterol while increasing HDL-cholesterol. Furthermore, FCME has been shown to decrease hepatic fat accumulation, suggesting potential applications in the management of metabolic syndrome and non-alcoholic fatty liver disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fermented cha-miang extract.